SR9009 (Stenabolic): The Metabolic and Endurance Enhancer

Active Substance: SR9009 (Stenabolic)
Manufacturer: Deus Medical
Pack: 50 Tablets in Container (10 mg/capsule)
Form: Oral (Capsule/Tablet)

What Is SR9009 (Stenabolic)?

SR9009, commonly known as Stenabolic, is a potent research drug that is often mistakenly classified as a SARM (Selective Androgen Receptor Modulator). It is, in fact, an agonist of the REV-ERBα/REV-ERBβ nuclear receptors.  

Originally developed by Professor Thomas Burris to study the body's circadian rhythm, SR9009 influences the body's biological clock and metabolism, leading to effects that mimic the benefits of exercise. For this reason, it is classified as a Hormone and Metabolic Modulator by the World Anti-Doping Agency (WADA).  

Core Functions and Mechanism

SR9009 works by activating the REV-ERB receptors, which play a pivotal role in regulating cellular energy.  

• Mitochondrial Biogenesis: SR9009 increases the number and efficiency of mitochondria (the cell's powerhouses) in skeletal muscle. This results in higher energy output and reduced fatigue.  

• Enhanced Energy Expenditure: By activating REV-ERBα, it alters the circadian pattern of metabolic genes in the liver and skeletal muscle, increasing overall energy expenditure and raising the Basal Metabolic Rate (BMR), even at rest.  

• Fatty Acid Oxidation: It enhances the metabolism of both fatty acids and glucose, promoting a switch to fat burning and accelerating fat loss.  

• Endurance Boost: Studies in animal models showed SR9009 significantly increased exercise capacity, leading to its illicit use by athletes for its potent ergogenic effects.  

 Usage and Dosage Protocols

Due to its short half-life, SR9009 requires strict, multiple-daily dosing to maintain stable levels, despite its oral form.  

• Recommended Dosage: The generally recommended dosage for misuse ranges between 10 mg to 30 mg per day. Beginners are advised to start at 10 mg per day.  

• Administration Frequency: Due to a relatively short half-life, SR9009 requires multiple daily doses to maintain stable plasma levels. A common protocol is to divide the total daily intake into two to three equal doses, taken approximately every 4 to 6 hours.  

• Cycling Protocol: To prevent the development of tolerance, cycles typically range from 8 to 12 weeks, followed by a minimum 4-week break.  

 Side Effects and Warnings

SR9009 is an investigational drug, and its long-term safety profile in humans is unknown.

• Circadian Rhythm Interference: Because SR9009 directly influences the body's clock, one of the most common user-reported side effects is disrupted sleep, increased wakefulness, and insomnia.  

• Anecdotal Effects: Other reported side effects include nausea and headache.  

• WADA Prohibition: SR9009 is explicitly placed on the World Anti-Doping Agency (WADA) Prohibited List under the category of Hormone and Metabolic Modulators due to its potent ergogenic effects on endurance.  

 Frequently Asked Questions (FAQs)

1. Why must SR9009 be taken multiple times per day despite being a capsule?

SR9009 has a very short half-life (approximately 4 hours). Although it is an oral capsule, it is cleared from the body quickly. To maintain stable activation of the REV-ERB receptors and sustain the metabolic and endurance-boosting effects throughout the day, the total dose must be split into 2-3 administrations.

2. Is SR9009 a SARM or a Metabolic Modulator?

SR9009 is a Metabolic Modulator, specifically a REV-ERBα agonist. It is often falsely advertised as a SARM on the black market, but it does not bind to the androgen receptor. It modulates metabolism, endurance, and fat burning primarily through its effect on mitochondrial function and the circadian clock.  

3. Does SR9009 suppress natural testosterone production?

No. Since SR9009 does not bind to the androgen receptor (AR), it does not interfere with the HPTA (Hypothalamic-Pituitary-Testicular Axis). Therefore, SR9009 cycles do not require standard Post Cycle Therapy (PCT) protocols using SERMs (like Nolvadex or Clomid).

4. What is the primary safety risk associated with SR9009?

The primary user-reported risks are related to disrupted sleep and circadian rhythm interference due to its REV-ERBα mechanism. As a research chemical not FDA-approved, the long-term systemic risks in humans are completely unknown, and it should be approached with extreme caution.